Shareholding disclosure

The Goldman Sachs Group, Inc

Declared position

5.54%

Threshold

Crossed upwards

Timeline

Published

11.02.2022

Transaction

07.02.2022

Voting rights breakdown

Voting rights acquired5.54%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAM2A00012

Beneficial owner

The Goldman Sachs Group, Inc

Declared address

The Goldman Sachs Group, Inc., Wilmington, DE 19801

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

The Goldman Sachs Group, Inc

Addex Therapeutics Ltd11.02.2022TAM2A00012

Disclosure summary

The Goldman Sachs Group, Inc disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 11.02.2022, at 5.54% of voting rights. Notice category: Single shareholder.

Disclosed position

5.54%

Voting rights acquired

Voting rights acquired5.54%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

The Goldman Sachs Group, Inc disclosed a holding in Addex Therapeutics Ltd, published on 11.02.2022.

Publication date11.02.2022

Transaction date07.02.2022

Issuing companyAddex Therapeutics Ltd

Beneficial ownerThe Goldman Sachs Group, Inc

Declared addressThe Goldman Sachs Group, Inc., Wilmington, DE 19801

CategorySingle shareholder

Voting rights acquired5.54%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAM2A00012

Source: SIX Exchange Regulation · Publication date: 11.02.2022

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open